INDSWFTLAB Stock Overview
Develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Ind-Swift Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹100.65 |
| 52 Week High | ₹186.00 |
| 52 Week Low | ₹89.50 |
| Beta | 0.26 |
| 11 Month Change | -14.54% |
| 3 Month Change | -26.10% |
| 1 Year Change | 8.46% |
| 33 Year Change | 26.52% |
| 5 Year Change | 289.36% |
| Change since IPO | 460.72% |
Recent News & Updates
There Are Some Reasons To Suggest That Ind-Swift Laboratories' (NSE:INDSWFTLAB) Earnings Are A Poor Reflection Of Profitability
Nov 20
Ind-Swift Laboratories Limited's (NSE:INDSWFTLAB) Revenues Are Not Doing Enough For Some Investors
Oct 20Recent updates
There Are Some Reasons To Suggest That Ind-Swift Laboratories' (NSE:INDSWFTLAB) Earnings Are A Poor Reflection Of Profitability
Nov 20Ind-Swift Laboratories Limited's (NSE:INDSWFTLAB) Revenues Are Not Doing Enough For Some Investors
Oct 20Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Stock Rockets 29% But Many Are Still Ignoring The Company
Jul 02Shareholders In Ind-Swift Laboratories (NSE:INDSWFTLAB) Should Look Beyond Earnings For The Full Story
May 21Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Surges 26% Yet Its Low P/E Is No Reason For Excitement
Apr 13Here's Why Ind-Swift Laboratories (NSE:INDSWFTLAB) Can Manage Its Debt Responsibly
Dec 28These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Reasonably Well
Jul 22Ind-Swift Laboratories (NSE:INDSWFTLAB) Has A Somewhat Strained Balance Sheet
Jul 12Did Business Growth Power Ind-Swift Laboratories' (NSE:INDSWFTLAB) Share Price Gain of 231%?
Feb 17We're Not So Sure You Should Rely on Ind-Swift Laboratories's (NSE:INDSWFTLAB) Statutory Earnings
Dec 30These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Extensively
Nov 11Is Ind-Swift Laboratories (NSE:INDSWFTLAB) A Risky Investment?
Jun 27Shareholder Returns
| INDSWFTLAB | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -5.1% | 0.5% | 0.5% |
| 1Y | 8.5% | 42.5% | 27.5% |
Return vs Industry: INDSWFTLAB underperformed the Indian Pharmaceuticals industry which returned 42.5% over the past year.
Return vs Market: INDSWFTLAB underperformed the Indian Market which returned 27.5% over the past year.
Price Volatility
| INDSWFTLAB volatility | |
|---|---|
| INDSWFTLAB Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: INDSWFTLAB has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: INDSWFTLAB's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 47 | Navrattan Munjal | www.indswiftlabs.com |
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson’s disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticancer, hypercholesterolemia, antimigraine, and thrombocytopenia. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, azithromycin dihydrate, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, clopidogrel hydrochloride, dapoxetine hydrochloride, donepezil hydrochloride, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nateglinide, nitazoxanide, nitrosamine, pazopanib hydrochloride, quetiapine hemifumarate, raltegravir potassium, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services.
Ind-Swift Laboratories Limited Fundamentals Summary
| INDSWFTLAB fundamental statistics | |
|---|---|
| Market cap | ₹5.95b |
| Earnings (TTM) | ₹3.73b |
| Revenue (TTM) | ₹7.42b |
1.6x
P/E Ratio0.8x
P/S RatioIs INDSWFTLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INDSWFTLAB income statement (TTM) | |
|---|---|
| Revenue | ₹7.42b |
| Cost of Revenue | ₹3.90b |
| Gross Profit | ₹3.52b |
| Other Expenses | -₹214.46m |
| Earnings | ₹3.73b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | 63.20 |
| Gross Margin | 47.41% |
| Net Profit Margin | 50.30% |
| Debt/Equity Ratio | 1.6% |
How did INDSWFTLAB perform over the long term?
See historical performance and comparison